REGARDSACCPresentationSlides.pptx

Validation of the Pooled Cohort 10-year Atherosclerotic Cardiovascular Disease Risk EquationsPaul Muntner, Lisandro D Colantonio, Mary Cushman, David C Goff Jr., George Howard, Virginia J Howard, Brett Kissela, Emily B Levitan, Donald M. Lloyd-Jones, Monika M Safford University of Alabama at Birmingham, University of Vermont, University of Colorado, University of Cincinnati, Northwestern University.On behalf of REGARDS and REGARDS-MIThis study was supported by U01 NS041588 (NINDS) and R01 HL080477, K24 HL111154 (NHLBI)Disclosures Drs. Muntner, Howard, Levitan, and Safford have received grant funding from Amgen Inc. for work unrelated to this presentation.Dr. Muntner has served on an advisory board for Amgen Inc.Drs. Cushman and Safford have served as consultants for DiaDexus.BackgroundIn 2013, the American College of Cardiology / American Heart Association (ACC/AHA) published a guideline for the estimation of atherosclerotic cardiovascular disease (ASCVD) risk.This guideline included the development of the Pooled Cohort risk equations for estimating 10-year risk for incident ASCVD. These equations can be used to guide the decision to initiate statins for people 40-79 years without ASCVD or diabetes and with LDL-C of 70 to 189 mg/dL – “clinically relevant population”. Consideration of statin treatment is recommended for adults with a 10-year ASCVD risk ≥ 7.5% Goff, J Am Coll Cardiol 2013; Stone, J Am Coll Cardiol 2013BackgroundThe Pooled Cohort risk equations were developed using data from several studies conducted before 2000. Marked declines in ASCVD incidence have occurred over the past 2 decades.These equations were reported to over-estimate risk in analyses of the Women’s Health Study, Women’s Health Initiative and the Physicians Health Study.Prior analyses: Did not focus on the population for whom the equations may inform a discussion to initiate statins.Did not have surveillance components Rosamond, Circulation 2012; Kleindorfer, Stroke 2010; Ridker, Lancet